Title: Application of Comprehensive Artificial Intelligence Retinal Expert (CARE) System: A National Real-World Evidence Study
Authors: Duoru Lin, Jianhao Xiong, Congxin Liu, Lanqin Zhao, Zhongwen Li, Shanshan Yu, Xiaohang Wu, Zongyuan Ge, et al., Daniel SW Ting, Tien Y Wong, Yuzhong Chen, and Haotian Lin
Publication Source: The Lancet Digital Health (2021)
Delivering specialized ophthalmic care in primary and community settings remains a major global challenge due to shortages of trained eye specialists. While AI algorithms have shown great success in controlled laboratory settings, proving their consistency across diverse real-world healthcare environments requires rigorous multi-center testing.
A nationwide prospective study published in The Lancet Digital Health evaluated the Comprehensive AI Retinal Expert (CARE) system—a unified deep-learning network designed to screen for 14 common retinal diseases simultaneously across real-world clinical workflows in China.
What Was the Study Testing?
Unlike traditional AI systems that use separate models for each disease, the CARE system utilizes a single multi-label convolutional neural network (Inception-ResNet-V2) trained on over 200,000 fundus photographs.
The system was evaluated across 35 real-world clinical environments:
- Diverse Clinical Environments: Deployed across tertiary hospitals, community clinics, and health physical examination centers.
- Broad Spectrum Coverage: Trained to detect 14 major retinal abnormalities, including referable diabetic retinopathy, glaucomatous optic neuropathy, pathological myopia, and age-related macular degeneration.
- Cross-Ethnicity & Hardware Generalization: Validated against external public datasets (such as EyePACS in the U.S.) to verify reliability across different ethnic groups and camera models.
Key Findings: Real-World Performance & Efficiency
The extensive real-world trial validated the robustness and operational efficiency of the CARE system:
1. Specialist-Level Diagnostic Accuracy
- Tertiary Hospitals: CARE achieved a mean AUC of 0.965 across 14 conditions, matching the diagnostic performance of senior ophthalmologists.
- Community Clinics & Exam Centers: Maintained outstanding accuracy in primary care settings, achieving mean AUCs of 0.983 in community hospitals and 0.953 in physical examination centers.
- Global Generalizability: When tested on the U.S. EyePACS dataset, CARE achieved an AUC of 0.960 for referable diabetic retinopathy, demonstrating strong performance across diverse populations and imaging hardware.
2. High Computational Efficiency
- Low Hardware Demand: By using a single neural network rather than 14 isolated models, CARE required only 3–6 GB of GPU RAM during operation.
- Field Deployability: The low computational footprint allows the software to run locally on standard desktop hardware in remote, low-resource primary clinics without requiring continuous cloud connectivity.
What Does This Mean for Healthcare & Screening?
The CARE study proves that a single AI model can reliably screen for multiple eye conditions simultaneously in real-world settings. By triaging patients at the primary care level, the system ensures that high-risk individuals are promptly referred to specialists while preventing secondary and tertiary hospitals from becoming overwhelmed with routine checkups.
This approach bridges the gap between urban medical hubs and underserved rural communities, bringing expert-level diagnostic support directly to primary healthcare providers.
The Bottom Line
The CARE system demonstrates that multi-disease AI screening is highly effective, efficient, and ready for deployment in everyday clinical settings. It provides a scalable solution for expanding access to specialized eye care worldwide.
Consult your eyecare professional to learn more about AI-assisted screenings and comprehensive eye health assessments.
Read the full open-access study in The Lancet Digital Health.